OGT’s Christmas challenge-throw a snowball to win an Amazon Kindle Fire

Put your skills to the test against friends and colleagues with OGT’s Snowball Challenge

Oxford, UK – 18 December 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is providing some festive fun this holiday season with its interactive Christmas Snowball Challenge. In the spirit of giving, OGT has once again decided to send an electronic Christmas card in place of paper cards and will instead make a donation to a number of charities.

The e-card features the return of OGT’s popular snowball game which invites you to put your ability to the test and see how far you can throw a snowball. Sounds easy? Use your skills to create the perfect sized snowball and judge the ideal wind speed. Challenge your friends and colleagues today and don’t forget to submit your score to the leader board as the furthest throw will win an Amazon Kindle Fire tablet. Good luck!

Visit OGT’s website to find out more about innovative cytogenetics research arrays, next generation sequencing (NGS) and array services and the company’s biomarker portfolio.

For a list of charities supported by OGT, please visit the company’s social responsibility page.

For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.com
W: www.ogt.com ; Twitter: @OxfordGeneTech

 

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.